Preliminary Findings Produce Near Complete Hair Regrowth
The National Alopecia Areata Foundation congratulates its advisors, Drs. Raphael Clynes, Angela Christiano and Julian Mackay-Wiggan, and their team at Columbia University Medical Center for their exciting preliminary findings with a drug approved by the FDA for the treatment of myelofibrosis (a type of bone marrow cancer) which has produced near complete hair regrowth in several patients with moderate-to-severe alopecia areata. We applaud the publication of these results in Nature Medicine.
This triumph is the result of a long history of Genome Wide Association Studies conducted by Dr. Christiano and supported by NAAF with well-characterized samples from the Registry, Biobank and Clinical Trials Network, a key component of our Alopecia Areata Treatment Development Program. Without quick and easy access to samples through the Registry – and the strategic framework of the Alopecia Areata Treatment Development Program and associated Research Summits – these breakthroughs would never have been realized in only a few short years. If you would like to help with future clinical trials, please join the Registry and add to our nearly 10,000 registrants.
While the results are encouraging, we wish to remind the alopecia areata community this is a preliminary study in a small population. Larger, more robust clinical trials are necessary to fully evaluate safety, efficacy and durability. JAK inhibitors as a class of drugs are potent immunosuppressive agents, and in patients with underlying diseases, have been associated with significant side effects.